ARTL's Losses Widen Amid Increased R&D, Aggressive Financing Moves

TL;DR

**ARTL is burning cash fast, relying on heavy dilution and a reverse split to stay afloat, making it a high-risk bet for traders.**

AI Summary

ARTELO BIOSCIENCES, INC. (ARTL) reported a net loss of $3,221 thousand for the three months ended June 30, 2025, an increase from $2,433 thousand in the prior year period, and a net loss of $5,593 thousand for the six months ended June 30, 2025, up from $4,916 thousand in the same period of 2024. Operating expenses rose to $3,150 thousand for the quarter and $5,529 thousand for the six months, driven by increased general and administrative expenses ($1,279 thousand vs. $827 thousand for the quarter) and research and development costs ($1,871 thousand vs. $1,685 thousand for the quarter). The company's cash and cash equivalents decreased to $2,066 thousand as of June 30, 2025, from $2,338 thousand at December 31, 2024. ARTL executed several financing activities, including issuing $900 thousand in convertible notes on May 1, 2025, and completing a private placement on June 24, 2025, generating net proceeds of $1,079 thousand from the sale of common stock and warrants. Post-period, ARTL entered an At-The-Market Offering Agreement for up to $6.5 million and an at-the-market PIPE for approximately $9,475 thousand in gross proceeds on August 4, 2025, to purchase SOL. A 1-for-6 reverse stock split was effective on June 13, 2025, reducing outstanding shares from 3,280,000 to approximately 546,667.

Why It Matters

ARTL's continued significant net losses and reliance on dilutive financing, including a recent 1-for-6 reverse stock split, signal a challenging path for investors. The company's aggressive capital raises, such as the $900 thousand convertible notes and the $1,079 thousand private placement, are critical for its 'going concern' status but will likely lead to substantial shareholder dilution. Competitors in the biopharmaceutical space with more robust pipelines or stronger financial positions may gain an advantage as ARTL focuses on funding operations. Employees face uncertainty given the company's precarious financial health, while customers and the broader market await tangible progress from its lipid-signaling therapeutics.

Risk Assessment

Risk Level: high — ARTL reported a net loss of $5,593 thousand for the six months ended June 30, 2025, and had only $2,066 thousand in cash and cash equivalents, raising substantial doubt about its ability to continue as a going concern. The company's accumulated deficit reached $55,729 thousand, and total stockholders' deficit was $(1,406) thousand as of June 30, 2025, indicating severe financial distress.

Analyst Insight

Investors should exercise extreme caution and consider avoiding ARTL given its significant losses, 'going concern' warning, and reliance on highly dilutive financing activities. Existing shareholders should evaluate their position in light of the substantial dilution from recent and planned offerings, and the 1-for-6 reverse stock split.

Financial Highlights

total Assets

$4,357 thousand

total Debt

$5,763 thousand

net Income

-$5,593 thousand

eps

-$9.80

cash Position

$2,066 thousand

Key Numbers

• $5,593 thousand — Net Loss (Increased from $4,916 thousand in prior year six-month period)
• $2,066 thousand — Cash and Cash Equivalents (Decreased from $2,338 thousand at December 31, 2024)
• $55,729 thousand — Accumulated Deficit (Increased from $50,136 thousand at December 31, 2024)
• $(1,406) thousand — Total Stockholders' Deficit (Shifted from $2,857 thousand equity at December 31, 2024)
• $900 thousand — Convertible Notes Proceeds (Issued on May 1, 2025, bearing 12.0% interest)
• $1,079 thousand — Private Placement Net Proceeds (From June 24, 2025, sale of common stock and warrants)
• 1-for-6 — Reverse Stock Split Ratio (Effective June 13, 2025, reducing outstanding shares)
• $6.5 million — ATM Offering Program (Maximum amount for future stock sales via R.F. Lafferty)
• $9,475 thousand — PIPE Gross Proceeds (Expected from August 4, 2025, at-the-market PIPE)
• $4,841 thousand — Accounts Payable and Accrued Liabilities (Increased from $1,676 thousand at December 31, 2024)

Key Players & Entities

• ARTELO BIOSCIENCES, INC. (company) — registrant
• R.F. Lafferty & Co., Inc. (company) — sales agent for ATM offering
• SEC (regulator) — approver of shelf registration
• $5,593 thousand (dollar_amount) — net loss for six months ended June 30, 2025
• $2,066 thousand (dollar_amount) — cash and cash equivalents as of June 30, 2025
• $900 thousand (dollar_amount) — gross proceeds from convertible notes issued May 1, 2025
• $1,079 thousand (dollar_amount) — net proceeds from private placement on June 24, 2025
• $6.5 million (dollar_amount) — maximum amount for At-The-Market Offering Agreement
• $9,475 thousand (dollar_amount) — expected gross proceeds from at-the-market PIPE on August 4, 2025
• Nevada (company) — state of incorporation

FAQ

Risk Factors

• Increasing Net Losses and Accumulated Deficit [high — financial]: The company reported a net loss of $3,221 thousand for Q2 2025, up from $2,433 thousand in Q2 2024. For the six months ended June 30, 2025, the net loss was $5,593 thousand, an increase from $4,916 thousand in the prior year period. This has led to an accumulated deficit of $55,729 thousand as of June 30, 2025, up from $50,136 thousand at December 31, 2024, indicating a persistent inability to generate profits.
• Deteriorating Stockholders' Equity [high — financial]: ARTL's total stockholders' equity has shifted to a deficit of $1,406 thousand as of June 30, 2025, a significant decline from a positive equity of $2,857 thousand at December 31, 2024. This negative equity position raises concerns about the company's long-term financial stability and solvency.
• Declining Cash Position Amidst Rising Expenses [high — financial]: Cash and cash equivalents decreased to $2,066 thousand as of June 30, 2025, from $2,338 thousand at December 31, 2024. Concurrently, operating expenses increased to $3,150 thousand for the quarter and $5,529 thousand for the six months, driven by higher G&A and R&D costs. This trend suggests a shrinking cash runway without further financing.
• Increased Accounts Payable and Accrued Liabilities [medium — financial]: Accounts payable and accrued liabilities have significantly increased to $4,841 thousand as of June 30, 2025, from $1,676 thousand at December 31, 2024. This substantial rise may indicate challenges in meeting short-term obligations or a deliberate strategy to extend payment terms.
• Reliance on Dilutive Financing [medium — financial]: The company has engaged in multiple financing activities, including issuing convertible notes and completing a private placement. Post-period, ARTL announced a $6.5 million ATM offering program and a $9.475 million PIPE. These actions, especially the ATM and PIPE, are dilutive to existing shareholders and highlight the company's ongoing need for capital.
• Impact of Reverse Stock Split [low — operational]: A 1-for-6 reverse stock split was effective on June 13, 2025, reducing outstanding shares from 3,280,000 to approximately 546,667. While intended to increase the stock price, reverse splits can sometimes signal underlying financial distress and may not address the fundamental business challenges.

Industry Context

The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like ARTL often rely heavily on external financing to fund operations and clinical trials. The competitive landscape is intense, with success often dependent on breakthrough discoveries and effective commercialization strategies.

Regulatory Implications

As a biotechnology company, ARTL is subject to stringent regulations from bodies like the FDA. Delays in clinical trials, failure to meet regulatory standards, or changes in healthcare policy can significantly impact operations and financial performance. Compliance with financial reporting regulations is also critical.

What Investors Should Do

1. Monitor cash burn rate closely given the declining cash position and increasing operating expenses.
2. Evaluate the dilutive impact of ongoing and planned financing activities (ATM, PIPE) on existing share value.
3. Assess the company's ability to achieve key clinical and regulatory milestones to justify continued investment.
4. Consider the implications of the growing accumulated deficit and negative stockholders' equity on long-term viability.
5. Analyze the terms and potential conversion impact of the outstanding convertible notes.

Key Dates

• 2025-05-01: Issuance of Convertible Notes — Provided $900 thousand in capital, but adds to future interest expense and potential dilution upon conversion.
• 2025-06-13: Reverse Stock Split — Reduced outstanding shares by a factor of 6, potentially impacting share price perception and liquidity without addressing core financial issues.
• 2025-06-24: Private Placement Completion — Generated $1,079 thousand in net proceeds from stock and warrant sales, further diluting existing shareholders.
• 2025-06-30: End of Second Quarter — Reporting period showing increased net loss and decreased cash reserves, highlighting ongoing financial challenges.
• 2025-08-04: At-The-Market (ATM) Offering and PIPE Agreement — Announced potential for up to $6.5 million via ATM and $9,475 thousand gross proceeds from a PIPE, indicating a significant need for capital and further dilution.

Glossary

Accumulated Deficit

The cumulative net losses of a company since its inception that have not been offset by profits. It represents a negative retained earnings balance. (Indicates the company has consistently operated at a loss, with the deficit growing to $55,729 thousand as of June 30, 2025.)

Convertible Notes

Debt instruments that can be converted into a predetermined amount of the issuer's equity at certain times during their life. (ARTL issued $900 thousand in convertible notes, adding debt that may convert to equity, increasing future share count.)

At-The-Market (ATM) Offering

A type of public offering where a company sells its stock directly into the open market over a period of time, typically through a broker or agent. (ARTL has an ATM program for up to $6.5 million, allowing for continuous, dilutive stock sales to raise capital.)

PIPE (Private Investment in Public Equity)

A private placement of securities by a publicly traded company to institutional investors or accredited investors. (ARTL is undertaking a PIPE for approximately $9,475 thousand, which will dilute existing shareholders but provide necessary capital.)

Reverse Stock Split

A corporate action to reduce the number of outstanding shares of stock by consolidating them into fewer, proportionally more valuable shares. (ARTL executed a 1-for-6 reverse split to increase its share price, effective June 13, 2025.)

Stockholders' Deficit

Occurs when a company's liabilities exceed its assets, resulting in a negative equity position for shareholders. (ARTL now has a stockholders' deficit of $1,406 thousand, indicating its liabilities outweigh its assets.)

Year-Over-Year Comparison

Compared to the prior year period, ARTL has seen a significant increase in net losses for both the three-month ($3,221k vs $2,433k) and six-month ($5,593k vs $4,916k) periods ending June 30, 2025. Operating expenses have also risen, particularly in general and administrative costs. While cash reserves have slightly decreased, the most striking change is the shift from positive stockholders' equity of $2,857k at December 31, 2024, to a deficit of $1,406k as of June 30, 2025, indicating a deteriorating financial position.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share ARTL The Nasdaq
• $5.82 — xercise price of $ 5.82 per share (the "$5.82 Warrants"), and (iv) warrants to purcha
• $10.00 — ercise price of $ 10.00 per share (the "$10.00 Warrants"). The Pre-Funded Warrants, th
• $10 — se and sale of securities at a price of $10.45, consisting of: (a) 906,687 shares o
• $10.20 — of common stock at an exercise price of $10.20 per share; and (c) three-year warrants
• $50.00 — of common stock at an exercise price of $50.00 per share, for expected aggregate gross
• $9,475 — gregate gross proceeds of approximately $9,475. The Company agreed that the net procee

Filing Documents

• artl_10q.htm (10-Q) — 1105KB
• artl_ex311.htm (EX-31.1) — 11KB
• artl_ex321.htm (EX-32.1) — 4KB
• 0001640334-25-001429.txt ( ) — 3971KB
• artl-20250630.xsd (EX-101.SCH) — 32KB
• artl-20250630_lab.xml (EX-101.LAB) — 219KB
• artl-20250630_cal.xml (EX-101.CAL) — 34KB
• artl-20250630_pre.xml (EX-101.PRE) — 190KB
• artl-20250630_def.xml (EX-101.DEF) — 114KB
• artl_10q_htm.xml (XML) — 464KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 3 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 30

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 71 Item 3. Defaults Upon Senior Securities 71 Item 4. Mine Safety Disclosures 71 Item 5. Other Information 71 Item 6. Exhibits 72

SIGNATURES

SIGNATURES 73 2 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION ARTELO BIOSCIENCES, INC. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) June 30, December 31, 2025 2024 ASSETS Current Assets Cash and cash equivalents $ 2,066 $ 2,338 Prepaid expenses and other current assets 167 219 Total Current Assets 2,233 2,557 Operating lease right-of-use assets 82 99 Intangible asset 2,039 2,039 Other assets 3 3 TOTAL ASSETS $ 4,357 $ 4,698 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable and accrued liabilities $ 4,841 $ 1,676 Accrued interest – convertible notes 18 - Due to related parties 26 61 Operating lease liabilities - current portion 36 35 Convertible notes 791 - Total Current Liabilities 5,712 1,772 Operating lease liabilities 51 69 TOTAL LIABILITIES 5,763 1,841 STOCKHOLDERS' EQUITY Preferred Stock, par value $ 0.001 , 69,445 shares authorized, 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024 - - Common Stock, par value $ 0.001 , 8,333,333 shares authorized and 704,425 and 567,582 shares issued and outstanding as of June 30, 2025, and December 31, 2024, respectively 1 1 Additional paid-in capital 54,617 53,194 Accumulated deficit ( 55,729 ) ( 50,136 ) Accumulated other comprehensive loss ( 295 ) ( 202 ) TOTAL STOCKHOLDERS' (DEFICIT) EQUITY ( 1,406 ) 2,857 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 4,357 $ 4,698 3 Table of Contents ARTELO BIOSCIENCES, INC. Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except per share data) Three months ended Six months ended June 30, June 30, 2025 2024 2025 2024 OPERATING EXPENSES General and administrative $ 1,279 $ 827 $ 2,274 $ 1,909 Research and development 1,871 1,685 3,255 3,192 Total Operating Expenses 3,150 2,512 5,529 5,101 Loss from Operations (

View Full Filing

View this 10-Q filing on SEC EDGAR